WALTHAM, Mass. — Revvity, Inc. (NYSE: RVTY) said it plans to introduce Signals Xynthetica™, a new AI-augmented design platform delivered as a Models-as-a-Service offering within the Revvity Signals software suite, aimed at accelerating molecular and materials discovery.
Signals Xynthetica is designed to integrate advanced in-silico design, predictive modeling, and experimental validation within a single governed environment. The platform will allow scientific teams to iteratively design, test, and refine candidate molecules and materials while continuously improving predictive accuracy through real experimental data.
Across life sciences and materials research, artificial intelligence and machine learning are increasingly shifting discovery efforts away from trial-and-error experimentation toward predictive, data-driven design. Revvity said the real-world impact of these technologies has been limited by a lack of tight integration between AI models, high-quality experimental data, and the workflows scientists use every day. Signals Xynthetica is intended to address this challenge by embedding AI models directly into the scientific context and linking predictions with wet-lab outcomes.
The platform will support multiple in-silico design approaches, including de novo molecule generation, property prediction, and multi-objective optimization. As a Models-as-a-Service offering, Signals Xynthetica will allow organizations to access and govern predictive models without the need to build or maintain complex AI infrastructure. Models can be applied consistently across projects, updated as new data becomes available, and evaluated alongside experimental results.
“AI has enormous potential to transform how molecules and materials are designed, but that potential is only realized when models are connected to real scientific workflows and data,” said Kevin Willoe, president of Revvity Signals Software. “Signals Xynthetica is about operationalizing predictive science by bringing in-silico design and experimental validation together in a continuous loop, accelerating discovery across industries.”
Revvity said Signals Xynthetica is expected to play a central role in the company’s broader strategy for AI-augmented discovery, helping customers scale predictive science while maintaining governance, data stewardship, and scientific rigor. Pre-registration for customers is underway, with early access programs expected to be available in the first half of 2026.
